Clinical trial
RBx11160 Phase II Dose Ranging Study RBx/MMV05-06
NCT00362050 · Medicines for Malaria Venture, Other · Completed
Key facts
| NCT number | NCT00362050 |
|---|---|
| Title | RBx11160 Phase II Dose Ranging Study RBx/MMV05-06 |
| Official title | A Phase II, Double-Blind, Parallel-Group, Randomized, Dose-Ranging Study Assessing the Antimalarial Activity and Safety of RBx 11160 Administered for 7 Days in Patients With Acute Uncomplicated Plasmodium Falciparum Malaria |
| Lead sponsor | Medicines for Malaria Venture, Other |
| Collaborators | Ranbaxy Laboratories Limited Industry Swiss Tropical & Public Health Institute |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Plasmodium Falciparum Malaria |
| Intervention type | Drug |
| Interventions | Treatment with 3 dose groups of RBx11160 over 7 days |
| Enrollment | 255 |
| Start date | Jun 1, 2006 |
| Completion | Jan 1, 2007 |
| First posted | Aug 9, 2006 |
| Last update posted | Aug 29, 2007 |
| Countries | India, Tanzania, Thailand |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: